- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01820598
Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients (StimobII)
Acute and Medium-term Effects of Neuromuscular Electrical Multisite System (Kneehab®) on Cardiovascular Parameters and Induced Muscle Fatigue in Morbidly Obese Patients: Comparison With the Unidirectional Standard Device
The study was designed to test the following hypotheses:
In patients with severe obesity, a multisite electrostimulation session (m-NMES) will induce higher changes in metabolic, inflammatory and cardiovascular parameters and higher increase in muscle strength during stimulated contractions than conventional unidirectional electrostimulation session (c-NMES).
In patients with severe obesity, a six-weeks m-NMES training program will enhance cardiovascular, metabolic and inflammatory parameters.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Background: Physical activity is known to reduce cardiovascular risk as far as even minor change in lifestyle could occur. In obesity, physical activity programs remain challenging due to multifactorial causes related to body mass such as shortness of breath, traumatological pain or psychosocial causes. Although neuromuscular electrical stimulation training is presently ignored in the management of obesity, this technique may be appropriate and useful for muscle deconditioning in these patients. Furthermore, direct effects of electrostimulation training program on vascular function have been previously reported in spinal cord injury and chronic heart disease, suggesting that improvement in cardiovascular function may be expected. While a promising new technique of multisite electrical stimulation (the Kneehab® system) has been recently commercialized, few study have investigated the acute effects of electrostimulation on vascular function and not any study report the effects of electrical stimulation in obese patients.
MAIN OUTCOME OF THE ACUTE PHASE STUDY (1st part):To study the effect of multisite electrical stimulation session (m-NMES) on arterial stiffness as compared to conventional unidirectional electrical stimulation session (c-NMES) in patients with severe obesity. Secondary outcomes of the observational study: 1/ To study the effect of m-NMES on endothelial function, blood pressure, systemic inflammation and metabolic status (fasting glucose and insulin) as well as electrically-induced muscle fatigue as compared with c-NMES in patients with morbid obesity. 2/ To study the profile of responders to electrical stimulation according to body composition, 6-minute walking distance, spontaneous physical activity or susceptibility to tolerate electrical stimulation. Response to electrical stimulation will be assessed by an improvement in arterial stiffness after stimulation, if so.
MAIN OUTCOME OF THE INTERVENTIONAL STUDY (2nd part):To study the effect of a multisite electrical stimulation training program (m-NMES) (6 weeks, 30 sessions) on arterial stiffness in patients with severe obesity. Secondary outcomes of the interventional study: To study the effect of m-NMES on endothelial function, blood pressure, systemic inflammation and metabolic status (fasting glucose and insulin) as well as muscle strength, body composition, functional capacity (6-minute walking distance) and spontaneous physical activity, after 15 sessions (3 weeks) and after 30 sessions (6 weeks) of training program. Evaluation of the dose-response to m-NMES training in terms of arterial stiffness and functional capacity.
Expected outcomes: Acute change in arterial stiffness and/or endothelial function is expected after one m-NMES session and/or after c-NMES session. M-NMES session is expected to induce higher changes than c-NMES stimulation session on cardiovascular and muscle parameters. Chronic changes in arterial stiffness and/or endothelial function is expected after 6 weeks of m-NMES training.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Grenoble, Francia
- Reclutamiento
- Hopital Universitaire
-
Contacto:
- Jean-Louis Pepin, MD, PhD
- Número de teléfono: 0476765516
- Correo electrónico: JPepin@chu-grenoble.fr
-
Contacto:
- Isabelle, Vivodtzev, PhD
- Número de teléfono: 0476510304
- Correo electrónico: i.vivodtzev@agiradom.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female, aged over 18 years
- Morbid obesity (BMI > 35 kg/m²)
- Not included into exercise training program in the year prior to inclusion- Spontaneous physical activity lower than 160 min wk (i.e. < 30 min/d x 5 d/wk).
Additional Inclusion criteria for the interventional study:
- Patients with PWV > 9.3 m / s
Exclusion Criteria:
- Underage- Pregnant or parturient women
- Persons deprived of their liberty for judicial or administrative reasons, person under a legal protection measure (article L1121-8)
- Exclusion period in other studies- Person not affiliated to a social security scheme
- Chronic alcoholism
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: m-NMES first
Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
|
Otros nombres:
|
|
Otro: c-NMES first
Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
|
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Delta arterial stiffness
Periodo de tiempo: Day1 and Day3
|
Change in carotid-femoral Pulse wave velocity (PWV) after NMES sessions
|
Day1 and Day3
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Delta pulse arterial tonus (RH-PAT)
Periodo de tiempo: Day1 and Day3
|
change in pulse arterial tonometry after NMES sessions
|
Day1 and Day3
|
|
NMES-induced muscle fatigue
Periodo de tiempo: Day1 and Day3
|
change in maximal voluntary contraction after NMES sessions
|
Day1 and Day3
|
|
Delta blood pressure
Periodo de tiempo: Day1 and Day3
|
changes in systolic and diastolic blood pressures after NMES sessions
|
Day1 and Day3
|
|
Delta plasmatic biomarkers
Periodo de tiempo: Day1 and Day3
|
changes in inflammatory and metabolic plasmatic biomarkers after NMES sessions
|
Day1 and Day3
|
|
Body composition
Periodo de tiempo: Day1, Day21 and Day 42
|
Fat-free mass and fat-free mass indexes assessed by impedancemetry
|
Day1, Day21 and Day 42
|
|
Spontaneous physical activity
Periodo de tiempo: Day1 and Day 42
|
Number of hours per day of physical activity at 1, 2, 3, 4 or 5 metabolic equivalent(METS),Number of step per day,using a 7-days actigraphy
|
Day1 and Day 42
|
|
Maximal voluntary contraction
Periodo de tiempo: Day1, Day21 and Day 42
|
Quadriceps peak force
|
Day1, Day21 and Day 42
|
|
Walking distance
Periodo de tiempo: Day1 and Day 42
|
6-minute-walking test
|
Day1 and Day 42
|
|
Arterial stiffness
Periodo de tiempo: Day1, Day21 and Day 42
|
Pulse wave velocity (PWV) measurements
|
Day1, Day21 and Day 42
|
|
Pulse artery tone (RH-PAT)
Periodo de tiempo: Day1, Day21 and Day 42
|
Pulse artery tonometry measurement
|
Day1, Day21 and Day 42
|
|
Plasmatic biomarkers
Periodo de tiempo: Day1, Day21 and Day 42
|
Inflammatory and metabolic biomarkers
|
Day1, Day21 and Day 42
|
|
Blood pressure
Periodo de tiempo: Day1, Day21 and Day 42
|
Arterial systolic and diastolic blood pressure
|
Day1, Day21 and Day 42
|
|
Response to m-NMES
Periodo de tiempo: Day42
|
Delta in current intensity during m-NMES between the first to the last session
|
Day42
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jean-Louis Pépin, MD, PhD, Laboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 12-AGIR-04
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .